Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$4.51 USD
+0.32 (7.64%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $4.51 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVXL 4.51 +0.32(7.64%)
Will AVXL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVXL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVXL
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
AVXL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
Other News for AVXL
Acadia Pharmaceuticals: Back In The Buy Zone
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Akero Therapeutics (AKRO)
Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030